What Upneeq ^®
(oxymetazoline hydrochloride
ophthalmic solution), 0.1%
Offers Your Patients

Upneeq is a first-in-class treatment—with a mechanism of action that lifts
upper eyelids

Directly activates α-adrenergic receptors in Müller’s muscle, stimulating contraction and elevation of the upper eyelids in adults with low-lying lids ¹
In vitro functional assays demonstrate that oxymetazoline has ≈5-fold greater affinity for α2 receptors ^2,3 than for
α1 receptors ^2,3
- The pharmacology of Upneeq has not been fully elucidated with respect to pharmacodynamic contribution of each receptor subtype

Upneeq stimulates Müller’s muscle to raise the upper eyelid ¹

Delivers rapid, visible lift to the upper eyelid with once-daily use

Mean change from baseline in upper eyelid elevation (MRD-1) after dosing Upneeq (data from pooled analysis of 2 clinical trials) ^*4

Upneeq (n=203)

Vehicle (n=101)

Error bars represent standard deviation of the mean change from baseline.

Upneeq increased upper eyelid elevation significantly more than vehicle in clinical trials, as measured by MRD-1 (on Day 1 and Day 14 of treatment) ¹
- Achieved average eyelid lift of 1mm ⁵
In one clinical trial, onset of elevation as shown by improvement in MRD-1 began in some patients 5 minutes after Upneeq was administered (the earliest time point measured) ⁵
- RVL-1201-202, Upneeq (n=109) vs. vehicle (n=55)

MRD-1=Marginal Reflex Distance 1 (distance from the central pupillary light reflex to the central margin of the upper lid).

Examples of positive results after the first dose of Upneeq

Actual patient images courtesy of Dr. Robert Schwarcz and Dr. Raymond Douglas. Individual results may vary. Average upper eyelid lift with Upneeq in clinical trials was 1mm.* ⁵

Achieves significant visual field improvement

Change from baseline in points seen in top 4 rows on LPFT (data from pooled analysis of 2 clinical trials)* ⁴

Upneeq (n=203)

Vehicle (n=101)

Error bars represent standard deviation of the mean change from baseline.

Upneeq demonstrated 3 times greater improvement in visual field compared to vehicle in clinical trials ( P<.01), as measured by LPFT (on Day 1 and Day 14 of treatment) ¹

LPFT=Leicester Peripheral Field Test (measuring superior visual field).

*Two randomized, multicenter, double-masked, vehicle-controlled, Phase 3 studies compared once-daily Upneeq in 304 subjects with acquired blepharoptosis. Efficacy was assessed with the Leicester Peripheral Field Test (LPFT) and photographic measurement of Marginal Reflex Distance (MRD-1). There was a statistically significant difference in mean change in the LPFT from baseline after instillation of Upneeq and vehicle, with significantly greater increases in the study eye of the Upneeq group evident at the 2-hour point and maintained at the 6-hour time point. Greater MRD-1 increases were observed for the Upneeq group than the vehicle group on Day 1 at 6 hours post-dose and on Day 14 at 2 hours post-dose. ¹

Safety and tolerability

In clinical trials, Upneeq safety was comparable to placebo

Most common adverse reactions (incidence 1%-5%): punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache ¹
2.2% of patients in clinical trials discontinued treatment due to an adverse event ⁵

Preservative-free and formulated with hypromellose

Hypromellose is a vehicle commonly used in artificial tear solutions and is comfortable for most patients ^6,7

High completion rate in clinical trials

97.5% of subjects completed Upneeq clinical trials ⁴
98% of subjects were compliant with dosing Upneeq once daily ⁴
94% of patients indicated no discomfort with Upneeq ⁵

EXPAND

COLLAPSE

INDICATION

UPNEEQ ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.

DRUG INTERACTIONS

Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. Upneeq ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. RVL Pharmaceuticals, Inc. 2020. 2. Hosten LO, Snyder C. Over-the-counter ocular decongestants in the United States - mechanisms of action and clinical utility for management of ocular redness. Clin Optom. 2020;12:95-105. 3. Haenisch B, Walstab J, Herberhold S, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010;24:729-739. 4. Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020;Epub ahead of print. 5. Data on file, RVL Pharmaceuticals, Inc. 6. EyeRounds.org. Larson T. Artificial tears: a primer. https://webeye.ophth.uiowa.edu/eyeforum/tutorials/ Artificial-Tears.htm. Accessed December 19, 2020. 7. Donshik P, Madden R, Simmons PA. Pursuing comfort in a multi-purpose solution. Contact Lens Spectrum. December 2000. https://www. clspectrum.com/issues/2000/december-2000/pursuing-comfort-in-a-multi-purpose-solution. Accessed December 19, 2020.

*Required Information
Please enter your first name
Please enter your last name
Please enter your practice name
Please enter your e-mail address
Please enter your ZIP
Please enter your phone number
Question This form is not intended for the reporting of adverse events or product complaints associated with the use of prescription drugs. For medical information or to report adverse events/product complaints, please email us at MedicalInfo@rvlpharma.com or call 877-482-3788.
* Specialty Please select specialty

What Upneeq ^®
(oxymetazoline hydrochloride
ophthalmic solution), 0.1%
Offers Your Patients

Upneeq is a first-in-class treatment—with a mechanism of action that lifts
upper eyelids

Upneeq stimulates Müller’s muscle to raise the upper eyelid ¹

Delivers rapid, visible lift to the upper eyelid with once-daily use

Examples of positive results after the first dose of Upneeq

Actual patient images courtesy of Dr. Robert Schwarcz and Dr. Raymond Douglas. Individual results may vary. Average upper eyelid lift with Upneeq in clinical trials was 1mm.* ⁵

Achieves significant visual field improvement

Safety and tolerability

In clinical trials, Upneeq safety was comparable to placebo

Preservative-free and formulated with hypromellose

High completion rate in clinical trials

ABOUT
ACQUIRED
BLEPHAROPTOSIS

GETTING YOUR
PATIENT STARTED
WITH UPNEEQ

RESOURCE
LIBRARY AND
FIND-A-SPECIALIST

What Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% Offers Your Patients

Upneeq is a first-in-class treatment—with a mechanism of action that lifts upper eyelids

Upneeq stimulates Müller’s muscle to raise the upper eyelid 1

Delivers rapid, visible lift to the upper eyelid with once-daily use

Examples of positive results after the first dose of Upneeq

Actual patient images courtesy of Dr. Robert Schwarcz and Dr. Raymond Douglas. Individual results may vary. Average upper eyelid lift with Upneeq in clinical trials was 1mm.* 5

Achieves significant visual field improvement

Safety and tolerability

In clinical trials, Upneeq safety was comparable to placebo

Preservative-free and formulated with hypromellose

High completion rate in clinical trials

ABOUT ACQUIRED BLEPHAROPTOSIS

GETTING YOUR PATIENT STARTED WITH UPNEEQ

RESOURCE LIBRARY AND FIND-A-SPECIALIST

INDICATION

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

What Upneeq ^®
(oxymetazoline hydrochloride
ophthalmic solution), 0.1%
Offers Your Patients

Upneeq is a first-in-class treatment—with a mechanism of action that lifts
upper eyelids

Upneeq stimulates Müller’s muscle to raise the upper eyelid ¹

Actual patient images courtesy of Dr. Robert Schwarcz and Dr. Raymond Douglas. Individual results may vary. Average upper eyelid lift with Upneeq in clinical trials was 1mm.* ⁵

ABOUT
ACQUIRED
BLEPHAROPTOSIS

GETTING YOUR
PATIENT STARTED
WITH UPNEEQ

RESOURCE
LIBRARY AND
FIND-A-SPECIALIST